Conference Track

Metastatic Breast Cancer

Source: CCO Independent Conference Coverage of the 2009 Annual Meeting of the AACR-CTRC San Antonio Breast Cancer Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Denosumab Superior to Zoledronic Acid in Delaying or Preventing SREs in Advanced Breast Cancer Patients With Bone Metastases
FACT: No Benefit With Addition of Fulvestrant to Anastrozole Therapy for the Treatment of Hormone Receptor–Positive Advanced Breast Cancer Patients After Relapse
In Phase III CONFIRM Trial, High-Dose Fulvestrant Prolongs Time to Progression in Postmenopausal Women With ER–Positive Advanced Breast Cancer
AVADO: Adding Bevacizumab to Docetaxel in First-line Treatment of Advanced Breast Cancer Improves PFS but Not OS
RIBBON-2: First Phase III Trial to Show PFS Benefit of Bevacizumab Plus Standard Chemotherapy in the Second-Line Treatment of Patients With MBC
Adding Sorafenib to Paclitaxel May Improve PFS in First-line Treatment of Patients With Advanced Breast Cancer
SOLTI-0701: Addition of Sorafenib to Capecitabine Significantly Improves PFS in Locally Advanced or Metastatic Breast Cancer
Sunitinib Associated With Shorter Median PFS Than Capecitabine in Previously Treated HER2-Negative Advanced Breast Cancer
Objective Response With Motesanib Plus Paclitaxel Comparable to Bevacizumab Plus Paclitaxel in First-line Treatment for HER2-Negative Metastatic Breast Cancer
Lapatinib Plus Trastuzumab Improves Overall Survival vs Lapatinib Alone in Progressive HER2-Positive Metastatic Breast Cancer
No Effect of Fcγ IIA and IIIA Receptor Polymorphisms on Trastuzumab Efficacy in Early or Metastatic HER2-Positive Breast Cancer
Trastuzumab DM-1 Proves Highly Effective and Well Tolerated in Extensively Pretreated HER2-Positive Metastatic Breast Cancer Patients

Expert Analysis

Metastatic Breast Cancer

Faculty:

Frankie Ann Holmes, MD, FACP
Clifford A. Hudis, MD
Kathy D. Miller, MD

George W. Sledge, Jr., MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss new findings on hormone therapies used for the treatment of postmenopausal women with hormone receptor–positive metastatic breast cancer
Summarize results of trials of new agents for the treatment of breast cancer with metastasis to the bone
Describe the use of targeted therapies for the treatment of HER2-positive advanced breast cancer
Consider evidence from studies evaluating new agents and combinations for the treatment of metastatic breast cancer
Provide appropriate care and counsel for patients and their families

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: February 25, 2010

Expiration Date: February 24, 2011

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing contact hours

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.